A5042778698- Urinary Bladder and Prostate Research
- Pelvic floor disorders treatments
- Urinary Tract Infections Management
- Gastroesophageal reflux and treatments
- Urological Disorders and Treatments
- Health and Wellbeing Research
- Pharmaceutical industry and healthcare
- Pain Management and Placebo Effect
- COVID-19 Digital Contact Tracing
- Social Media in Health Education
- Data-Driven Disease Surveillance
- Academic Publishing and Open Access
- Pharmacology and Obesity Treatment
- Pediatric Urology and Nephrology Studies
- Cardiovascular Syncope and Autonomic Disorders
- COVID-19 epidemiological studies
New York University
2022-2024
Icahn School of Medicine at Mount Sinai
2011-2014
Pfizer (United States)
2007-2010
Johnson University
2007
To compare the efficacy and tolerability of fesoterodine 8 mg with tolterodine extended-release (ER) 4 placebo in a randomized clinical trial patients an overactive bladder (OAB).In this 12-week double-blind, double-dummy, placebo-controlled, trial, eligible reported OAB symptoms for > or = 3 months recorded voids 1 urgency urinary incontinence (UUI) episode per 24 h 3-day diaries at baseline. Patients were 2:2:1 ratio to (4 week then 11 weeks); ER mg; (with sham dose escalation placebo)....
To evaluate the efficacy and tolerability of flexible-dose fesoterodine in subjects with overactive bladder (OAB) who were dissatisfied previous tolterodine treatment.This was a 12-week, open-label, study adults OAB (> or = 8 micturitions > 3 urgency episodes per 24 h) had been treated (immediate- extended-release) for within 2 years screening reported dissatisfaction treatment. Subjects received 4 mg once daily weeks; thereafter, dosage maintained at increased to based on subject's...
Abstract Aims To characterize the response to fesoterodine treatment for overactive bladder (OAB) in subjects who did or not choose dose escalate a flexible‐dose study. Methods Subjects were randomized 4 mg placebo. At week 2, could remain on (non‐escalators) increase 8 (escalators) remaining 10 weeks (sham escalation placebo). completed 3‐day diaries at baseline, 2 and 12 noting micturitions, urgency episodes, urinary incontinence (UUI) episodes. Results Sixty‐three per cent of 438 73% 445...
Abstract Aims To assess the efficacy and tolerability of fesoterodine 8 mg versus tolterodine extended release (ER) 4 in subjects with overactive bladder (OAB) stratified by age (<65, 65–74, ≥75 years). Methods This was a post hoc analysis data from two double‐blind trials. Subjects reporting ≥1 urgency urinary incontinence (UUI) episode ≥8 micturitions/24 hr at baseline were randomized to (4 for 1 week, 11 weeks), ER mg, or placebo. completed 3‐day diaries, Urgency Perception Scale...
Abstract Objective This study sought to evaluate whether synthetic data derived from a national coronavirus disease 2019 (COVID-19) dataset could be used for geospatial and temporal epidemic analyses. Materials Methods Using an original (n = 1 854 968 severe acute respiratory syndrome 2 tests) its derivative, we compared key indicators of COVID-19 community spread through analysis aggregate zip code-level curves, patient characteristics outcomes, distribution tests by code, indicator counts...
Study Type – Therapy (cohort) Level of Evidence 2b What’s known on the subject? and What does study add? We know that bladder‐relaxing agents antimuscrinics act symptoms overactive bladder are first treatment in such patients. fesoterodine is a newer antimuscarinic with good activity safety profile. This adds to experience changing dose as often needed by patients, decision can be made change clinical result. OBJECTIve To assess changes (OAB) patient‐reported outcomes post hoc analysis which...
Objective: To assess the effects of tolterodine extended release (ER) on patient-reported outcomes (PROs) in sexually active women with overactive bladder (OAB) and urgency urinary incontinence (UUI).
Study Type – Therapy (cohort) Level of Evidence 2b What’s known on the subject? and What does study add? Fesoterodine is an effective treatment for overactive bladder. However, length time until effects begin to be seen was not known. The demonstrates that effect 4 mg bladder symptoms can at one week. OBJECTIVE To assess onset efficacy fesoterodine once daily (OAB) after 1 week treatment. PATIENTS AND METHODS This a prespecified analysis data collected during first 12‐week, open‐label,...
No AccessJournal of UrologyAdult Urology1 May 2012The Effect Elective Sham Dose Escalation on the Placebo Response During an Antimuscarinic Trial for Overactive Bladder Symptoms David R. Staskin, Martin C. Michel, Franklin Sun, Zhonghong Guan, and Jon D. Morrow StaskinDavid Staskin Tufts University School Medicine, Boston, Massachusetts , MichelMartin Michel Amsterdam, The Netherlands SunFranklin Sun Pfizer, Inc., New York, York GuanZhonghong Guan MorrowJon Mount Sinai View All Author...
Objective:Fesoterodine is an antimuscarinic agent indicated for the treatment of overactive bladder (OAB) symptoms. The objective this study was to evaluate efficacy fesoterodine versus placebo over selected intervals during a 24-hour period in subjects with OAB.Research design and methods:In post hoc analysis, data were analyzed from two randomized, double-blind, placebo-controlled 12-week phase III trials which history OAB symptoms ≥6 months treated morning doses 4 mg, 8 or...